Azacitidine for Myelodysplastic Syndrome

Share :
Published: 19 Feb 2009
Views: 15039
Dr Lewis Silverman - Myelodysplastic Syndrome & Myeloproliferative Disease Center, New York
Discusses his role in the AZA trial, the findings and higher and lower risk MDS patient responses. Interviewed at ASH 2009. Lewis Silverman is an Associate Professor of Medicine and Director of the Myelodysplastic Syndrome and Myeloproliferative Disease Program, Mount Sinai School of Medicine, in New York City. He served as Principal Investigator of the randomised Phase III trial of Azacitidine vs. Supportive Care which served as the basis for approval of Azacitidine by the FDA for MDS in the United States.